Detalhe da pesquisa
1.
Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients: A Retrospective Case-Control Study.
J Infect Dis
; 229(4): 1041-1049, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37956413
2.
Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies.
J Infect Dis
; 2023 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37996072
3.
Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
J Neurol Neurosurg Psychiatry
; 95(1): 19-28, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37479463
4.
Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization.
Eur J Neurol
; 30(9): 2781-2792, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310391
5.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
J Infect Dis
; 225(3): 502-509, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415048
6.
Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
Clin Infect Dis
; 74(6): 1093-1096, 2022 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34166499
7.
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.
Clin Infect Dis
; 74(4): 707-710, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050731
8.
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.
Eur J Clin Microbiol Infect Dis
; 41(3): 445-454, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34997388
9.
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
J Antimicrob Chemother
; 76(6): 1553-1557, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33693680
10.
Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir.
J Antimicrob Chemother
; 76(8): 2148-2152, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33930161
11.
Prevalence of genotypic baseline risk factors for cabotegravirâ+ârilpivirine failure among ARV-naive patients.
J Antimicrob Chemother
; 76(11): 2983-2987, 2021 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34015097
12.
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
J Antimicrob Chemother
; 76(7): 1893-1897, 2021 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33855355
13.
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
J Antimicrob Chemother
; 76(2): 477-481, 2021 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33099638
14.
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
J Antimicrob Chemother
; 76(9): 2400-2406, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34100068
15.
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
J Antimicrob Chemother
; 75(4): 1026-1030, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31976534
16.
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
J Antimicrob Chemother
; 75(7): 1943-1949, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32259255
17.
Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries.
J Antimicrob Chemother
; 74(2): 462-467, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30418575
18.
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
J Antimicrob Chemother
; 74(3): 614-617, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30476106
19.
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.
J Antimicrob Chemother
; 74(9): 2716-2722, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31273376
20.
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
J Antimicrob Chemother
; 74(9): 2742-2751, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31269208